Manish Jain, PhD, MBA (@jainmk6) header
Manish Jain, PhD, MBA (@jainmk6) profile picture

Assistant Professor Department of Translational Neurosciences College of Medicine - Phoenix University of Arizona, Phoenix, AZ

Phoenix, AZ
Joined August 2019
Photo by Manish Jain, PhD, MBA (@jainmk6)Photo by Manish Jain, PhD, MBA (@jainmk6)Photo by Manish Jain, PhD, MBA (@jainmk6)
I’m excited to share that I’ll be joining the Department of Translational Neurosciences, College of Medicine–Phoenix at the University of Arizona as an Assistant Professor (Tenure-Track) in July 2026! #GPCR #Neuroscience #DrugDiscovery #StructuralBiology #UniversityOfArizon
4
3
35
3,499
Manish Jain, PhD, MBA retweeted
In three patients with refractory epilepsy, hippocampal chemogenetic therapy plus low-dose clozapine was associated with a mean seizure-frequency reduction of 92.6%. Adverse events were grade 1 or 2. Full study results: nej.md/4Agtyhz
3
51
11
167
52,763
Manish Jain, PhD, MBA retweeted
Three people with epilepsy resistant to drug treatment saw the number of seizures they had per month fall by more than 90%, after gene-laden viruses were infused directly into their brains go.nature.com/3WrLS8G
13
72
6
294
26,916
Manish Jain, PhD, MBA retweeted
A major milestone for Chemogenetics. DREADD technology demonstrates therapeutic efficacy in humans. A new study published today in NEJM demonstrates preliminary safety and therapeutic benefit from DREADD-based chemogenetic treatment of refractory epilepsy, marking an extraordinary milestone for neuroscience and precision medicine. nejm.org/doi/full/10.1056/NE… The approach combines targeted AAV gene delivery at the epileptogenic locus with very low, subthreshold doses of clozapine to activate engineered DREADD receptors and modulate neuronal activity. Congratulations to Bryan Roth, whose pioneering discovery of DREADDs made this field possible, and to the investigators of the NEJM study for bringing this technology to patients. This achievement has a particularly meaningful connection to our work published in Science Magazine in 2017. science.org/doi/10.1126/scie… We showed that clozapine, rather than CNO itself, is the active mediator of DREADD activation in vivo and proposed that subthreshold doses of clozapine could be used to activate DREADDs in humans, anticipating a practical path toward clinical translation. At the time, many in the scientific community viewed these findings primarily as relevant to the design of preclinical DREADD experiments. We saw a much broader opportunity, translating Chemogenetics into human therapeutics. Nearly a decade later, that vision is now becoming a reality. Our 2017 study was supported by the research funding through the National Institutes of Health (NIH) and The National Institute on Drug Abuse (NIDA), a prime example of how fundamental basic research can ultimately enable transformative clinical applications. This is an exciting beginning, but larger, well-controlled studies are essential to establish the magnitude and durability of therapeutic benefit and long-term safety. Chemogenetics is moving beyond an experimental neuroscience tool toward a potentially transformative neuroscience platform. We are only beginning to realize its potential.
1
49
5
156
10,101
Manish Jain, PhD, MBA retweeted
☕️ Why does coffee taste bitter? Research from Dr. Bryan Roth’s lab @zenbrainest reveals how the human bitter taste receptor TAS2R43 recognizes caffeine and other compounds naturally found in roasted and brewed coffee! dailycoffeenews.com/2026/07/…
3
2
264
Manish Jain, PhD, MBA retweeted
An interesting article, although GoA is the major Gi-like G protein in the brain (1% of total brain protein): Gi Signaling Does Not Differentiate Hallucinogenic from Nonhallucinogenic 5-HT2A Receptor Agonists pubs.acs.org/acncdm/article-…
2
4
27
2,501
Manish Jain, PhD, MBA retweeted
This is huge!! @NIMHDirector will allocate $$$ to fund, essentially, clinical trial networks for #psychedelics and other rapidly-acting psychoactives (#ketamine #mdma ) grants.nih.gov/grants/guide/…
3
9
39
4,641
Manish Jain, PhD, MBA retweeted
#hiring #postdoc #jobalert My lab is seeking a Postdoctoral Research Associate to work on GPCRs pharmacology and drug discovery. Interested candidates can apply: arizona.csod.com/ux/ats/care…
4
22
1
62
5,951
Manish Jain, PhD, MBA retweeted
🧠 What if we could unlock the therapeutic potential of psychedelics without the hallucinations? Dr. Bryan Roth’s research @zenbrainest on LSD and serotonin receptors was recently featured in SciShow’s “LSD May Lead to a New Kind of Medicine”! youtube.com/watch?v=lkMtbeU2…
5
1
8
1,501
#hiring #postdoc #jobalert My lab is seeking a Postdoctoral Research Associate to work on GPCRs pharmacology and drug discovery. Interested candidates can apply: arizona.csod.com/ux/ats/care…
4
22
1
62
5,951
Manish Jain, PhD, MBA retweeted
An innovator in the field of biomedical investigation, Manish Jain, PhD, has joined #uazmedphx's Department of Translational Neurosciences as a tenure-track assistant professor. Read about his studies and career accomplishments here: bit.ly/4yQlRhp
2
5
295
Manish Jain, PhD, MBA retweeted
A suite of engineered mice for interrogating psychedelic drug actions #psychedelics Congrats to Yi-ting, Ariel, Bill, Gavin, Dewran, Pierre and too many others to mention. A yuuge effort and we hope that folks will find these mice useful nature.com/articles/s41593-0…
14
3
44
10,191
Manish Jain, PhD, MBA retweeted
A proud scientific parent--congrats to @jainmk6 ! Now with his own lab phoenixmed.arizona.edu/trans…
2
2
2
31
2,899
Manish Jain, PhD, MBA retweeted
I'm attending the Brain Initiative meeting--big announcement tomorrow
1
4
22
2,676